Market Place
Sourcing Support
Enliven Therapeutics Reports Q3 Financial Results & Update
13 Nov 2024 //
PR NEWSWIRE
Enliven Therapeutics to Present at Jefferies London Conf.
07 Nov 2024 //
PR NEWSWIRE
Enliven Therapeutics Announces Positive Data From Phase 1 Trial
28 Sep 2024 //
GLOBENEWSWIRE
Enliven To Present ELVN-001 Phase 1a Data At CML Conference
18 Sep 2024 //
GLOBENEWSWIRE
Enliven Therapeutics Reports Q2 Results And Business Update
13 Aug 2024 //
GLOBENEWSWIRE
Enliven Therapeutics to Present at Two Upcoming Investor Conferences
29 May 2024 //
GLOBENEWSWIRE
Enliven Therapeutics Reports Q1 Financial Results, Business Update
14 May 2024 //
GLOBENEWSWIRE
Enliven: Positive ELVN-001 Phase 1 Chronic Myeloid Leukemia Data
11 Apr 2024 //
GLOBENEWSWIRE
Enliven Therapeutics Appoints Dr. Lori Kunkel to Board of Directors
09 Apr 2024 //
GLOBENEWSWIRE
Enliven Therapeutics to Share Initial Data from Ph 1 Clinical Trial of ELVN-001
28 Mar 2024 //
GLOBENEWSWIRE
Enliven Therapeutics Announces $90 M Private Placement Financing
19 Mar 2024 //
GLOBENEWSWIRE
Enliven Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results
14 Mar 2024 //
GLOBENEWSWIRE
Enliven Therapeutics to Present at TD Cowen™s 44th Annual Health Care Conference
27 Feb 2024 //
GLOBENEWSWIRE
Enliven Therapeutics Reports Third Quarter 2023 Financial Results
09 Nov 2023 //
GLOBENEWSWIRE
Enliven Therapeutics Reports Second Quarter 2023 Financial Results
10 Aug 2023 //
GLOBENEWSWIRE
Enliven Therapeutics to Present at Two Upcoming Investor Conferences
31 May 2023 //
GLOBENEWSWIRE
Enliven Therapeutics Reports First Quarter 2023 Financial Results
11 May 2023 //
GLOBENEWSWIRE
Enliven Closes Merger with Imara and Private Placement of $165 Million
23 Feb 2023 //
GLOBENEWSWIRE
Copyright © 2025 LePro PharmaCompass OPC Private Limited, All rights reserved.